CV Science

Frederic Delom Oncology & Gynaecology Laboratory (OncoGyne)

Course and current status

From 2025 - : Group leader - "Oncology & Gynaecology Laboratory" (OncoGyne) - Inserm U1312.

From 2022 - : Inserm team leader - “Reprograming tumour activity & associated microenvironment” - Inserm U1312.

2016 - 2024 : Group leader - ARTiSt group.

From 2016 - : Assistant Professor, University of Bordeaux, Bordeaux.

2011- 2016: University-Inserm chair, University of Bordeaux, Bordeaux

2007 - 2010: Post-doctoral position, Barts and The London, London, UK.

2004 - 2006: Post-doctoral position, McGill University, Montreal, Canada.

2001 - 2004: Scientist position, Aventis Pharmaceutical Company, Paris, France.

1998 - 2001: PhD Thesis, INSERM U38, Marseille, France.

Scientific summary

The OncoGyne Laboratory focuses on translational research in malignant gynaecological tumours, in close partnership with the Institut Bergonié. Our work aims to advance the understanding of tumour biology and improve patient care.

Our research is structured around three main axes:

• ARTiSt (G. Babin & F. Delom): Deciphering the molecular and cellular mechanisms driving gynaecological tumours.

• MATRIX (S. Croce & D. Fessart): Enhancing the detection and characterisation of gynaecological cancers to improve patient stratification and enable more personalised follow-up.

• RAPID (F. Guyon): Optimising diagnosis and clinical decision-making through innovative approaches with direct impact on therapeutic management.

We also develop, through our POETIC platform, analytical tools for biomarker quantification and for screening chemical and peptide libraries. This infrastructure enables the identification of therapeutic targets and the validation of new treatment strategies.

Our projects integrate fundamental, translational, and clinical research. They rely on patient cohorts treated at the Institut Bergonié as well as on a range of preclinical models, including cell lines and patient-derived mouse models, to test and validate discoveries emerging from our fundamental and translational studies.